StockNews.com Initiates Coverage on CEL-SCI (NYSE:CVM)

StockNews.com began coverage on shares of CEL-SCI (NYSE:CVM) in a research note issued to investors on Wednesday. The brokerage issued a sell rating on the stock.

CEL-SCI Stock Down 7.9 %

Shares of CVM opened at $0.37 on Wednesday. CEL-SCI has a one year low of $0.36 and a one year high of $3.08. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.18 and a current ratio of 0.64. The stock has a market capitalization of $24.33 million, a price-to-earnings ratio of -0.63 and a beta of 0.65. The stock has a 50 day moving average price of $0.63 and a 200 day moving average price of $0.95.

Institutional Trading of CEL-SCI

Several institutional investors and hedge funds have recently bought and sold shares of CVM. Black Diamond Financial LLC lifted its holdings in shares of CEL-SCI by 35.8% in the 2nd quarter. Black Diamond Financial LLC now owns 72,000 shares of the company’s stock valued at $84,000 after buying an additional 19,000 shares during the period. Renaissance Technologies LLC raised its position in CEL-SCI by 29.9% during the second quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock worth $202,000 after acquiring an additional 40,000 shares during the last quarter. Calton & Associates Inc. purchased a new stake in CEL-SCI in the 3rd quarter valued at approximately $50,000. Geode Capital Management LLC boosted its stake in shares of CEL-SCI by 9.6% during the third quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after acquiring an additional 53,879 shares during the last quarter. Finally, Thoroughbred Financial Services LLC grew its holdings in shares of CEL-SCI by 140.9% during the second quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock worth $158,000 after buying an additional 80,001 shares in the last quarter. Hedge funds and other institutional investors own 12.08% of the company’s stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.